Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 75.44% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 06/21/2023 | 75.44% | Truist Securities | $22 → $24 | Maintains | Buy |
| 06/21/2023 | 82.75% | Cantor Fitzgerald | → $25 | Reiterates | Overweight → Overweight |
| 06/20/2023 | 75.44% | Truist Securities | $22 → $24 | Maintains | Buy |
| 05/12/2023 | 75.44% | HC Wainwright & Co. | → $24 | Reiterates | Buy → Buy |
| 03/20/2023 | 75.44% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 01/19/2023 | 60.82% | Truist Securities | $18 → $22 | Maintains | Buy |
| 12/21/2022 | 31.58% | Truist Securities | $17 → $18 | Maintains | Buy |
| 12/21/2022 | 75.44% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 12/20/2022 | 46.2% | Piper Sandler | $18 → $20 | Maintains | Overweight |
| 08/24/2022 | 13.3% | Roth Capital | $10 → $15.5 | Downgrades | Buy → Neutral |
| 08/11/2022 | 24.27% | Truist Securities | $12 → $17 | Maintains | Buy |
| 08/11/2022 | 31.58% | HC Wainwright & Co. | $12 → $18 | Maintains | Buy |
| 02/08/2022 | -12.28% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 03/18/2021 | -48.83% | Roth Capital | $6.5 → $7 | Maintains | Buy |
| 08/12/2020 | -41.52% | Truist Securities | $10 → $8 | Maintains | Buy |
| 05/13/2020 | -26.9% | SunTrust Robinson Humphrey | $11 → $10 | Maintains | Buy |
| 02/14/2020 | -12.28% | Cantor Fitzgerald | $11 → $12 | Reiterates | → Overweight |
| 12/13/2018 | -45.18% | Piper Sandler | $5 → $7.5 | Maintains | Overweight |
| 11/29/2018 | -41.52% | Cantor Fitzgerald | → $8 | Reiterates | → Overweight |
| 09/21/2018 | -41.52% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/21/2023 | 75.44% | HC Wainwright & Co. | → 24 美元 | 重申 | 购买 → 购买 |
| 06/21/2023 | 75.44% | 信托证券 | 22 美元 → 24 美元 | 维护 | 购买 |
| 06/21/2023 | 82.75% | 坎托·菲茨杰拉德 | → 25 美元 | 重申 | 超重 → 超重 |
| 06/20/2023 | 75.44% | 信托证券 | 22 美元 → 24 美元 | 维护 | 购买 |
| 05/12/2023 | 75.44% | HC Wainwright & Co. | → 24 美元 | 重申 | 购买 → 购买 |
| 03/20/2023 | 75.44% | HC Wainwright & Co. | → 24 美元 | 重申 | → 购买 |
| 01/19/2023 | 60.82% | 信托证券 | 18 美元 → 22 美元 | 维护 | 购买 |
| 2022 年 12 月 21 日 | 31.58% | 信托证券 | 17 美元 → 18 美元 | 维护 | 购买 |
| 2022 年 12 月 21 日 | 75.44% | HC Wainwright & Co. | 18 美元 → 24 美元 | 维护 | 购买 |
| 2022 年 12 月 20 日 | 46.2% | 派珀·桑德勒 | 18 美元 → 20 美元 | 维护 | 超重 |
| 2022 年 8 月 24 日 | 13.3% | 罗斯资本 | 10 美元 → 15.5 美元 | 降级 | 买入 → 中性 |
| 08/11/2022 | 24.27% | 信托证券 | 12 美元 → 17 美元 | 维护 | 购买 |
| 08/11/2022 | 31.58% | HC Wainwright & Co. | 12 美元 → 18 美元 | 维护 | 购买 |
| 2022 年 8 月 2 日 | -12.28% | HC Wainwright & Co. | 9 美元 → 12 美元 | 维护 | 购买 |
| 03/18/2021 | -48.83% | 罗斯资本 | 6.5 美元 → 7 美元 | 维护 | 购买 |
| 08/12/2020 | -41.52% | 信托证券 | 10 美元 → 8 美元 | 维护 | 购买 |
| 05/13/2020 | -26.9% | SunTrust 罗宾逊汉弗莱 | 11 美元 → 10 美元 | 维护 | 购买 |
| 02/14/2020 | -12.28% | 坎托·菲茨杰拉德 | 11 美元 → 12 美元 | 重申 | → 超重 |
| 2018 年 12 月 13 日 | -45.18% | 派珀·桑德勒 | 5 美元 → 7.5 美元 | 维护 | 超重 |
| 11/29/2018 | -41.52% | 坎托·菲茨杰拉德 | → 8 美元 | 重申 | → 超重 |
| 09/21/2018 | -41.52% | 坎托·菲茨杰拉德 | → 8 美元 | 启动覆盖开启 | → 超重 |
What is the target price for Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmicals（CPRX）的目标价格是多少？
The latest price target for Catalyst Pharmaceuticals (NASDAQ: CPRX) was reported by HC Wainwright & Co. on July 21, 2023. The analyst firm set a price target for $24.00 expecting CPRX to rise to within 12 months (a possible 75.44% upside). 13 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年7月21日公布了Catalyst Pharmicals（纳斯达克股票代码：CPRX）的最新目标股价。这家分析公司将目标股价定为24.00美元，预计CPRX将在12个月内升至12个月内（可能上涨75.44％）。去年有13家分析公司公布了评级。
What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?
分析师对Catalyst Pharmicals（CPRX）的最新评级是多少？
The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ: CPRX) was provided by HC Wainwright & Co., and Catalyst Pharmaceuticals reiterated their buy rating.
Catalyst Pharmicals（纳斯达克股票代码：CPRX）的最新分析师评级由HC Wainwright & Co. 提供，Catalyst Pharmicals重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmicals（CPRX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Catalyst Pharmicals的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Catalyst Pharmicals的最新评级是在2023年7月21日提交的，因此你应该预计下一个评级将在2024年7月21日左右公布。
Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?
分析师对 Catalyst Pharmicals (CPRX) 的评级正确吗？
While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $0.00 to $24.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $13.68, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Catalyst Pharmicals（CPRX）评级得到了重申，目标股价为0.00美元至24.00美元。Catalyst Pharmicals（CPRX）目前的交易价格为13.68美元，在分析师的预测区间内。